This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

Logo

The Effect of Inulin in Irritable Bowel Syndrome

Sponsored by Mardin Artuklu University

About this trial

Last updated 2 years ago

Study ID

377

Status

Completed

Type

Interventional

Phase

N/A

Placebo

No

Accepting

19 to 65 Years
All Sexes

Trial Timing

Ended 3 years ago

What is this trial about?

Purpose: This study was conducted to evaluate the effect of inulin on bowel symptoms, depression and quality of life in individuals with constipation-dominant irritable bowel syndrome. Individuals (n=34) aged 21-63 years with constipation-dominant IBS were included in the study. Individuals were divided into two groups as prebiotic group \[(n=17) (inulin/oligofructose 50/50 mixture of 4.6 g (Inulin=total 9.2 g) inulin/oligofructose 50/50 mixture twice a day)\], and placebo \[(n=17), (Maltodextrin=9.2 g)\] group. The intervention period was 8 weeks and Bristol Stool Scale, IBS-Visual Analogue Scale, IBS-Symptom Severity Score Scale (IBS-SSS), IBS-Quality of Life Scale (IBS-QoL) and Beck Depression Scale were administered to the participants at the beginning, 1st month and 2nd month. SPSS software programme was used for statistical analysis of the data. It is thought that inulin supplementation may be effective in reducing symptom severity and frequency, improving bowel function (stool frequency, consistency and transit time) and quality of life, and thus may be beneficial in individuals with constipation-predominant IBS.

What are the participation requirements?

Inclusion Criteria

* the individuals were between 19-65 years of age

* volunteer to participate in the study

* Individuals diagnosed with IBS by a physician according to Rome IV criteria

Exclusion Criteria

* a history of gastrointestinal surgery (except appendectomy and cholecystectomy)

* inflammatory bowel disease

* lactose malabsorption

* gastroenteritis

* celiac disease

* gastric

* duodenal ulcer

* metabolic diseases (cardiac, hepatic and renal diseases, diabetes, etc.)

* history of malignancy

* pregnancy and lactation

* use of intestinal motility

* antidepressant drugs

* involuntary body weight loss of more than 5 kg in the last 3 months

* use of dietary fibre supplements in the last 3 months

* use of antibiotics in the last 3 months

* use of prebiotic and probiotic supplements in the last 3 months.